Please login to the form below

Not currently logged in
Email:
Password:

EC approves Pegasys

Roche has revealed that the European Commission approved its hepatitis C medicine, Pegasys. The company says the drug could lead to patients being cured in four months
Roche has revealed that the European Commission (EC) approved its hepatitis C medicine, Pegasys. The company says the drug could lead to patients being cured in four months.

It has been developed as a 16-week treatment for the genotype 2 and 3 strains of hepatitis C in patients with low virus levels. The company hopes that the shorter treatment rates will reduce patients' exposure to drug therapies.

Previous to the approval of Pegasys, patients had to undergo 24 weeks of treatment, even if they had low virus levels and rapid response rates to the medicine.

William Burns, CEO of Roche pharmaceuticals division, explained that the company is committed to advancing the use of personalised medicine, which accounts for patients' reaction and medical history.

"This approval for 16 weeks of treatment in genotype 2 and 3 patients with a rapid response demonstrates the value of using diagnostic tools to determine an individual treatment regime and hopefully will encourage more eligible patients to come forward for treatment," he said.

26th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics